Founder of Philadelphia Life Sciences Firms Targets RNA as Key to Knocking Out Covid-19
Veenu Aishwarya, founder and CEO of AUM LifeTech and AUM BioTech and COV-IRT member is featured in this story.
From bizjournals.com
Feature image from bizjournals.com, Jeff Fusco
“Veenu Aishwarya’s two Philadelphia life sciences companies have jointly launched a research program called “Knockdown Coronavirus,” which has a goal of developing a treatment for Covid-19.
The initiative combines the resources of AUM LifeTech Inc., a preclinical stage biotech company developing RNA therapeutics, and AUM BioTech, a genetic research startup.
“We are very excited to launch this program and serve the global scientific community, which is working tirelessly to find a cure for Covid-19 in these unique and challenging times,” said Aishwarya, the founder and CEO of both companies.
AUM LifeTech and AUM BioTech — both based at the Cambridge Innovation Center in uCity Square — want to provide their self-delivering RNA silencing research products and technology to the global coronavirus research community to facilitate research and accelerate the pace of therapeutic development…”